BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Bacterial infections clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for bacterial infections: 252 (145 sponsors; 53 newly posted in the last 180 days, 5 stopped in the last 180 days; 28 new-entrant sponsors). Momentum score 19.8, rank 30 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 40, Phase 2 67, Phase 3 56, Phase 4 10, N/A 79.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Pfizer PFE | 14 | P3 7, P2 4, P1 1, NA 2 | 5 | 7 |
| CanSino Biologics Inc. | 13 | NA 4, P2 1, P4 1, P1 3, P3 4 | 5 | 2 |
| Incyte Corporation INCY | 6 | P3 4, P1 1, P2 1 | 0 | 2 |
| Sinovac Biotech Co., Ltd SVA | 4 | P3 4 | 0 | 3 |
| Novartis Pharmaceuticals NVS | 14 | NA 9, P3 3, P4 1, P1 1 | 3 | 4 |
| Sanofi SNY | 6 | P2 2, P3 2, NA 1, P1 1 | 1 | 2 |
| AbbVie ABBV | 5 | NA 1, P2 2, P3 2 | 0 | 2 |
| Sinovac Life Sciences Co., Ltd. | 5 | P1 2, P3 2, P2 1 | 1 | 1 |
| Basilea Pharmaceutica | 2 | P3 2 | 0 | 0 |
| GlaxoSmithKline | 13 | P2 3, P1 7, NA 1, P3 1, P4 1 | 2 | 5 |
| Institut Pasteur | 5 | NA 4, P3 1 | 1 | 2 |
| Aimei Vacin BioPharm (Zhejiang) Co., Ltd. | 2 | P1 1, P3 1 | 0 | 0 |
| Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 2 | P1 1, P3 1 | 0 | 0 |
| Sanofi Pasteur, a Sanofi Company SNY | 2 | NA 1, P3 1 | 0 | 1 |
| UCB Biopharma SRL | 2 | P1 1, P3 1 | 0 | 1 |
| AVVA Pharmaceuticals Ltd. | 1 | P3 1 | 0 | 0 |
| Baxis Pharmaceuticals, Inc. | 1 | P3 1 | 0 | 0 |
| Beijing Minhai Biotechnology Co., Ltd | 1 | P3 1 | 0 | 0 |
| Biofabri, S.L | 1 | P3 1 | 0 | 0 |
| Bluefin Biomedicine, Inc. | 1 | P3 1 | 0 | 0 |
| Chengdu CoenBiotech Co., Ltd | 1 | P3 1 | 0 | 0 |
| China National Biotec Group Company Limited | 1 | P3 1 | 0 | 0 |
| Grifols Therapeutics LLC GRFS | 1 | P3 1 | 0 | 0 |
| ISTx, LLC new entrant | 1 | P3 1 | 1 | 0 |
| Kaneka Americas Holding Inc. | 1 | P3 1 | 0 | 1 |
New-entrant sponsors: ISTx, LLC.
Recently stopped trials
- NCT02354014 Janssen Research & Development, LLC - suspended: As part of the protocol-specified interim pharmacokinetic (PK) evaluation in Study TMC207-C211, PK data demonstrated lower-than-anticipated Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of M
- NCT05178862 Scynexis, Inc. - terminated: Strategic decision not related to safety or efficacy concerns for Ibrexafungerp. A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed b
- NCT06685835 Insmed Incorporated - terminated: Lack of Efficacy A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
- NCT06241573 Boehringer Ingelheim - terminated: A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurat
- NCT05327803 AN2 Therapeutics, Inc - terminated: EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study. Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-24 est. | P1/P2 | CanSino Biologics Inc. | NCT07600983 Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) | Streptococcus Pneumoniae Infection | recruiting | 854 |
| 2026-12 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT07089186 Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections | Hospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP); Comp | recruiting | 80 |
| 2026-12 est. | P2 | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | NCT07413094 Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS | Sepsis | recruiting | 309 |
| 2026-12-30 est. | P2/P3 | Beijing Continent Pharmaceutical Co, Ltd. | NCT07388680 Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia | Radiation-induced Lung Injury; Immune-related Pneumonia | recruiting | 298 |
| 2026-12-31 est. | P3 | Materia Medica Holding | NCT06284265 Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial Cystitis | Cystitis Chronic; Cystitis Bacterial; Recurrence of Chronic Bacterial Cystitis | active not recruiting | 415 |
| 2027-01 est. | P2 | Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) | NCT06672978 A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acut | Acute Pyelonephritis; Complicated Urinary Tract Infection | active not recruiting | 66 |
| 2027-01-24 est. | P2 | Chengdu Syncor Pharmaceutical Co., Ltd. | NCT07483671 Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV Patients | Bacterial Vaginosis | not yet recruiting | 80 |
| 2027-02-11 est. | P2 | AstraZeneca AZN | NCT07215702 A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. | Sepsis; Acute Kidney Injury | recruiting | 124 |
| 2027-02-15 est. | P3 | CanSino Biologics Inc. | NCT07017777 A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) | Pneumococcal Infections; Streptococcal Infections; Bacterial Infections | active not recruiting | 600 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-15 est. | P2 | ImmunityBio, Inc. IBRX | NCT07492888 Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) | Acute Respiratory Distress Syndrome; Severe Community-Acquired Pneum; Sepsis; Lymphopenia / Immunopa | withdrawn | |
| 2026-09-22 | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06841731 A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia | Hospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP) | completed | 120 |
| 2026-09-01 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT06569056 A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis | Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP) | completed | 579 |
| 2026-09 est. | P2 | Vasomune Therapeutics, Inc. | NCT05123755 Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia. | Acute Respiratory Distress Syndrome; Viral or Bacterial Infections; Pneumonia; Pneumonia, Viral; Res | active not recruiting | 60 |
| 2026-08-03 est. | P2 | Catalysis SL | NCT07179237 Efficacy of Carminal in Helicobacter Pylori Gastritis | H Pylori Gastritis; H Pylori Infection; H Pylori Eradication; Gastritis Associated With Helicobacter | recruiting | 80 |
| 2026-07 est. | P2 | Saptalis Pharmaceuticals LLC | NCT07146217 Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection | Bacterial Infections | not yet recruiting | 30 |
| 2026-06-29 | P3 | Vivacelle Bio | NCT06072430 A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02) | Septic Shock; Sepsis; Hypovolemia | completed | 39 |
| 2026-06-06 | P3 | Colgate Palmolive CL | NCT07471477 Bacterial Reduction for a Manual Toothbrush With a 360-Degree Mouth Cleaner Design Versus a Standard Toothbrush | Bacterial Load Reduction | completed | 56 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "bacterial infections"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.